July 2004
Time;7/19/2004, Vol. 164 Issue 3, p85
The article discusses how the link between PSA blood-test results and prostate cancer has seen its share of controversy. A recent study found that some men developed the cancer even when their PSA readings were normal. A new study suggests that it is the rate of increase in a man's PSA level, not the level itself, that determines the risk of death from the disease.


Related Articles

  • PROSTATE DEBATE. Song, Sora // Time International (South Pacific Edition);6/7/2004, Issue 22, p63 

    The article presents information on a study that revealed a major problem in the PSA test, the standard blood screen for prostate cancer. The test measures blood levels of a protein released by the prostate. For years doctors assumed that a reading lower than 4 ng/mL of blood meant the patient...

  • Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients. Noveski, Predrag; Madjunkova, Svetlana; Sukarova Stefanovska, Emilija; Matevska Geshkovska, Nadica; Kuzmanovska, Maja; Dimovski, Aleksandar; Plaseska-Karanfilska, Dijana // PLoS ONE;1/8/2016, Vol. 11 Issue 1, p1 

    Background: Although age-related loss of chromosome Y (LOY) in normal hematopoietic cells is a well-known phenomenon, the phenotypic consequences of LOY have been elusive. However, LOY has been found in association with smoking, shorter survival and higher risk of cancer. It was suggested that...

  • JOHNS HOPKINS DEVELOPS COLON CANCER BLOOD TEST.  // Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p7 

    Focuses on a blood test developed by researchers at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute with Indivumed for the diagnosis of colon cancer. Cancer genes detected in the blood of colorectal cancer patients; Background of Indivumed.

  • Prostat iÄŸne biyopsisi ve radikal prostatektomi materyallerinde gleason skorlarının karşılaÅŸtırılması. Kürşat Bozkurt, Kemal; Kızmaz, Mustafa; İnan Mamak, Gülsün; Korkmaz, İsmail; Bircan, Sema // Medical Journal of Suleyman Demirel University;2013, Vol. 20 Issue 3, p93 

    Aim: Gleason score (GS) is an important prognostic marker for prostate cancer and it is strongly correlated with stage and prognosis. However, needle biopsy (NB) GS is not always consistent with that of radical prostatectomy (RP) specimens. In this study, the correlation of GSs of NB and RP...

  • HOW MUCH BLOOD IS ENOUGH? AN EVIDENCE-BASED STUDY ON THE MINIMUM BLOOD VOLUME REQUIRED FOR LABORATORY TESTS. Rodriguez, Wanda; McCarty, Doreen; O'Donnell, AnnMarie; Kane, Joyce; Nolan, Stephanie; Carlese, Cristina // Oncology Nursing Forum;Mar2007, Vol. 34 Issue 2, p527 

    Frequent blood sampling for laboratory testing can be an unnecessary source of blood loss in the critically ill oncology patient. The increased number of analytes measured combined with increased frequency in testing and easier collection with arterial and venous catheters can directly lead to...

  • PCa patients more likely to die of other causes. Dosa, Laszlo // Urology Times;Jul2002, Vol. 30 Issue 7, p6 

    Relates the results of a study showing that prostate cancer patients are more likely to die from non-prostate cancer causes. Need for physicians to pay attention to other diseases that may affect the prostate cancer patient.

  • Half of watchful waiting patients seek Tx in 3 years. Overmyer, Mac // Urology Times;Jun2003, Vol. 31 Issue 6, p12 

    Reports on a study showing that half of watchful waiting prostate cancer patients are seeking treatment in three years. Most common reason for intervention; Substantially high percentage of patients who changed their minds and decided to pursue treatment for no clinical reasons that could be...

  • Surviving Antioxidant Supplements. Bjelakovic, Goran; Gluud, Christian // JNCI: Journal of the National Cancer Institute;5/16/2007, Vol. 99 Issue 10, p742 

    The article discusses various reports published within the issue, including one about the results of a perspective observational study on multivitamin use and prostate cancer and another on the ongoing clinical trials and further studies of pharmaceutical drugs used for prostate cancer patients.

  • Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS). Bremner, K E; Mitsakakis, N; Wilson, L; Krahn, M D // Prostate Cancer & Prostatic Diseases;Mar2014, Vol. 17 Issue 1, p98 

    A correction to the article "Predicting Utility Scores for Prostate Cancer: Mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS)" published in a previous issue of "Prostate Cancer and Prostatic Disease" is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics